• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌中免疫组织化学检测HER2/neu蛋白过表达与荧光原位杂交(FISH)之间的相关性:发展中国家的问题

Correlation between HER2/neu protein overexpression on Immunohistochemistry and Fluorescent in Situ Hybridization (FISH) in breast carcinoma: Problems in developing countries.

作者信息

Mukhtar Zubaria, Faisal Amina, Mudassir Ghazala, Mamoon Nadira

机构信息

Zubaria Mukhtar, FCPS Department of Histopathology, Shifa International Hospital, Islamabad, Pakistan.

Amina Faisal, Resident Histopathology Department of Histopathology, Shifa International Hospital, Islamabad, Pakistan.

出版信息

Pak J Med Sci. 2023 Nov-Dec;39(6):1814-1817. doi: 10.12669/pjms.39.6.6704.

DOI:10.12669/pjms.39.6.6704
PMID:37936749
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10626075/
Abstract

OBJECTIVE

To correlate the results of HER2/neu protein overexpression on immunohistochemistry (IHC) and gene amplification on fluorescence in situ hybridization (FISH) and to document the problems faced in performing FISH procedure.

METHODS

This was an observational retrospective study covering five years from January 1, 2015 - December 31, 2019 at Histopathology Department of Shifa International Hospital (SIH), Islamabad. All cases of breast cancer that underwent florescence in situ hybridization (FISH) were retrieved. Correlation between HER2/neu overexpression on IHC and its amplification on FISH was analyzed. Problems in application of FISH were recorded.

RESULTS

Out of 451 cases submitted for HER2/neu testing by FISH, 68 cases (15%) were rejected. Gene amplification was seen in 139 (36.29%) cases. Total cases with HER2/neu IHC score of 2+ were 330 cases and out of which gene amplification was seen in 98 cases (29.69%) whereas 93.1% (41/44) 3+ IHC cases were amplified. Poor fixation, inadequate amount of tumor with crushing artefacts and dye application to the biopsy fragments were causes of sample rejection.

CONCLUSIONS

Her2/neu amplification was seen in most Her2/neu 3+ cases and approximately one-third of Her2neu 2+ cases. Proper fixation, adequate biopsy material with standardized processing is required to yield useful results on FISH.

摘要

目的

将免疫组织化学(IHC)检测的HER2/neu蛋白过表达结果与荧光原位杂交(FISH)检测的基因扩增结果进行关联分析,并记录FISH检测过程中遇到的问题。

方法

这是一项回顾性观察研究,时间跨度为2015年1月1日至2019年12月31日的五年,研究地点为伊斯兰堡希法国际医院(SIH)病理科。检索所有接受荧光原位杂交(FISH)检测的乳腺癌病例。分析IHC检测中HER2/neu过表达与其在FISH检测中的扩增之间的相关性。记录FISH检测应用过程中出现的问题。

结果

在451例接受FISH检测HER2/neu的病例中,68例(15%)被拒收。139例(36.29%)检测到基因扩增。HER2/neu IHC评分为2+的病例共有330例,其中98例(29.69%)检测到基因扩增,而IHC评分为3+的病例中93.1%(41/44)检测到基因扩增。固定不佳、肿瘤组织量不足伴有挤压伪像以及将染料应用于活检碎片是样本被拒收的原因。

结论

大多数HER2/neu 3+病例以及约三分之一的HER2neu 2+病例检测到Her2/neu基因扩增。FISH检测需要适当固定、足够的活检材料并采用标准化处理流程才能得出有用的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd4d/10626075/b349eb50e86a/PJMS-39-1814-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd4d/10626075/a6373782ce36/PJMS-39-1814-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd4d/10626075/986c19c7ae2c/PJMS-39-1814-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd4d/10626075/b349eb50e86a/PJMS-39-1814-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd4d/10626075/a6373782ce36/PJMS-39-1814-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd4d/10626075/986c19c7ae2c/PJMS-39-1814-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd4d/10626075/b349eb50e86a/PJMS-39-1814-g003.jpg

相似文献

1
Correlation between HER2/neu protein overexpression on Immunohistochemistry and Fluorescent in Situ Hybridization (FISH) in breast carcinoma: Problems in developing countries.乳腺癌中免疫组织化学检测HER2/neu蛋白过表达与荧光原位杂交(FISH)之间的相关性:发展中国家的问题
Pak J Med Sci. 2023 Nov-Dec;39(6):1814-1817. doi: 10.12669/pjms.39.6.6704.
2
Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.乳腺癌和卵巢癌患者胸腹水Her2/neu基因扩增与蛋白过表达的联合检测
J Cancer Res Clin Oncol. 2010 Sep;136(9):1389-400. doi: 10.1007/s00432-010-0790-2. Epub 2010 Mar 9.
3
Chromogenic Hybridization Technique versus Immunohistochemistry in Assessment of HER2/neu Status in 448 Iraqi Patients with Invasive Breast Carcinoma.显色杂交技术与免疫组织化学在448例伊拉克浸润性乳腺癌患者HER2/neu状态评估中的比较
Open Access Maced J Med Sci. 2019 Jun 30;7(12):1917-1925. doi: 10.3889/oamjms.2019.342.
4
Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.乳腺癌中HER2/neu的实验室检测:预测靶向治疗反应的不断发展的策略。
Cancer Control. 2001 Sep-Oct;8(5):415-8. doi: 10.1177/107327480100800504.
5
HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases.荧光原位杂交(FISH)与免疫组织化学(IHC)检测122例疑难胃癌病例中HER2基因扩增情况的比较
Appl Immunohistochem Mol Morphol. 2016 Aug;24(7):459-64. doi: 10.1097/PAI.0000000000000219.
6
FISH and HER2/ equivocal immunohistochemistry in breast carcinoma.乳腺癌中的荧光原位杂交(FISH)及人表皮生长因子受体2(HER2)/免疫组化结果不明确
Indian J Cancer. 2019 Apr-Jun;56(2):119-123. doi: 10.4103/ijc.IJC_333_18.
7
Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.子宫浆液性乳头状癌中HER2/neu状态的测定:免疫组织化学与荧光原位杂交的比较分析
Gynecol Oncol. 2005 Jul;98(1):24-30. doi: 10.1016/j.ygyno.2005.03.041.
8
HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma.胃腺癌中HER2癌基因扩增与免疫组织化学分析
Discoveries (Craiova). 2018 Dec 31;6(4):e83. doi: 10.15190/d.2018.6.
9
Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?乳腺癌中HER-2/neu过表达和/或基因扩增的评估:原位杂交应成为首选方法吗?
APMIS. 2003 Mar;111(3):444-50. doi: 10.1034/j.1600-0463.2003.t01-1-1110210.x.
10
Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.HER2/neu 状态测定:比较细胞块上 HER2/neu 双原位杂交 DNA 探针鸡尾酒检测与组织学标本上免疫组化和荧光原位杂交的初步研究
Arch Pathol Lab Med. 2014 Apr;138(4):553-8. doi: 10.5858/arpa.2013-0314-SA.

本文引用的文献

1
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients.比较 HER2 阳性乳腺癌患者中存在 HER2 过表达与 HER2 扩增的肿瘤。
BMC Cancer. 2022 Mar 5;22(1):242. doi: 10.1186/s12885-022-09351-4.
2
Frequency Of Hormone Receptors And Her-2/Neu Receptor Positivity In Different Histology In Breast Cancer Patients.
J Ayub Med Coll Abbottabad. 2020 Jul-Sep;32(3):323-326.
3
Cancer prevalence in Pakistan: meta-analysis of various published studies to determine variation in cancer figures resulting from marked population heterogeneity in different parts of the country.巴基斯坦的癌症患病率:对各种已发表研究的荟萃分析,以确定由于该国不同地区人口异质性明显而导致的癌症数据差异。
World J Surg Oncol. 2018 Jul 5;16(1):129. doi: 10.1186/s12957-018-1429-z.
4
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.人表皮生长因子受体 2 检测在乳腺癌中的应用:美国临床肿瘤学会/美国病理学家学会临床实践指南的重点更新。
Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382. doi: 10.5858/arpa.2018-0902-SA. Epub 2018 May 30.
5
Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients.巴基斯坦患者腔面 A 型和腔面 B 型乳腺癌内在亚型的预后参数。
World J Surg Oncol. 2018 Jan 2;16(1):1. doi: 10.1186/s12957-017-1299-9.
6
HER2/ Testing In 432 Consecutive Breast Cancer Cases using FISH and IHC - A Comparative Study.采用荧光原位杂交(FISH)和免疫组化(IHC)对432例连续性乳腺癌病例进行人表皮生长因子受体2(HER2)检测——一项对比研究
J Clin Diagn Res. 2017 Apr;11(4):EC01-EC05. doi: 10.7860/JCDR/2017/25625.9521. Epub 2017 Apr 1.
7
Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.乳腺癌中Her2/neu状态的测定:一项使用免疫组织化学和荧光原位杂交双重检测方法的单机构经验。
Am J Clin Pathol. 2017 Apr 1;147(4):432-437. doi: 10.1093/ajcp/aqw224.
8
Incidence and Mortality and Epidemiology of Breast Cancer in the World.全球乳腺癌的发病率、死亡率及流行病学
Asian Pac J Cancer Prev. 2016;17(S3):43-6. doi: 10.7314/apjcp.2016.17.s3.43.
9
The assessment of HER2 status in breast cancer: the past, the present, and the future.乳腺癌中HER2状态的评估:过去、现在与未来。
Pathol Int. 2016 Jun;66(6):313-24. doi: 10.1111/pin.12407. Epub 2016 Apr 7.
10
Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.乳腺癌中HER2状态的评估:12年间单机构通过荧光原位杂交和免疫组织化学检测的总体阳性率及准确性:一项质量控制研究
BMC Cancer. 2013 Dec 30;13:615. doi: 10.1186/1471-2407-13-615.